VCM
SNDX icon

Versant Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Versant Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Hold
844
– – ﹤0.01% 1975
2026
Q1 		$19.7K Hold
844
– – ﹤0.01% 1828
2025
Q4 		$17.7K Hold
844
– – ﹤0.01% 1716
2025
Q3 		$13K Buy
844
+22
+3% +$288 ﹤0.01% 1816
2025
Q2 		$7.7K Buy
+822
New +$9.05K ﹤0.01% 2002
2025
Q1 		– Sell
-689
Closed -$9.11K – 2613
2024
Q4 		$9.11K Buy
+689
New +$11.8K ﹤0.01% 1450
2023
Q4 		– Sell
-10
Closed -$145 – 2006
2023
Q3 		$145 Sell
10
-13
-57% -$246 ﹤0.01% 1905
2023
Q2 		$481 Buy
+23
New +$479 ﹤0.01% 1842

Other funds holding SNDX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
HPBT
Hickory Point Bank & Trust Decatur, Illinois $165M AUM 27.01% 1-Year Est. Return

Versant Capital Management's SNDX Position: Q2 2026 in Review

Versant Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 844 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

Versant Capital Management first reported a position in SNDX in Q2 2023 and has held it in 8 quarters since. The position peaked at $19.7K in Q1 2026. 17 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Versant Capital Management held 844 shares of Syndax Pharmaceuticals worth $18.4K as of Q2 2026.
  • Versant Capital Management left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1975 holding.
  • Versant Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
  • Versant Capital Management's Syndax Pharmaceuticals position peaked at $19.7K in Q1 2026.
  • 17 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.